

Knockdown of the prion gene expression by RNA interference in bovine fibroblast cells

Shaohua Wang · Xiaoqing Lv · Kun Zhang ·
Tonghui Lin · Xiaofang Liu · Jing Yuan ·
Yunping Dai · Ning Li

Received: 20 September 2009 / Accepted: 2 October 2009
© Springer Science+Business Media B.V. 2009

Abstract *PRNP* is the gene encoding prion protein whose misfolded and β -sheet-rich isoform is the infectious agent of transmissible spongiform encephalopathy (TSE). TSE, also called prion diseases, cause fatal neurodegenerative and transmissible disorders in human and animals. Among these diseases, bovine spongiform encephalopathy (BSE) has tremendous impact on economy and human health in the world. In the present study, we hypothesize suppression of the *PRNP* gene expression could raise resistance to BSE in cattle by using vector-based small interfering RNA (siRNA) expression systems. Therefore, the objective was to screen effective DNA-encoding short hairpin RNAs (shRNAs) which could knockdown the *PRNP* gene expression in bovine fibroblast cells. Human U6 promoter was employed to drive

shRNA transcription from the DNA vector, and seven shRNAs, that designed to target coding region and 3' untranslated region of the *PRNP* gene, were selected. Four out of seven shRNAs tested were found to be effective in inhibiting the *PRNP* gene expression, and the most significant suppression level was as much as 62.9% evidenced by real-time RT-PCR. Furthermore, the protein abundance was obviously reduced compared to the control. Overall, the present study demonstrated that vector-based siRNA expression systems is an efficient approach to knockdown the *PRNP* gene expression in bovine fibroblast cells and thereby provide donor cells for somatic cell nuclear cloning to produce cattle that is resistant to prion related diseases.

Keywords Prion · RNA interference · Bovine · Fibroblast cells · shRNA

S. Wang · X. Lv · K. Zhang · T. Lin · X. Liu · J. Yuan ·
Y. Dai (✉) · N. Li (✉)

State Key Laboratory for Agrobiotechnology, College of Biological Science, China Agricultural University, Yuanmingyuan West Road No. 2, Haidian District, Beijing 100193, People's Republic of China
e-mail: daiyunping@sina.com

N. Li
e-mail: ninglcau@cau.edu.cn

S. Wang
e-mail: shwang510@gmail.com

Y. Dai · N. Li
Beijing Gene & Protein Biotechnology Co., Ltd., Room 306, Zhongding Building, Malianwa North Road No.158, Haidian District, Beijing 100193, People's Republic of China

Present Address:

K. Zhang
Animal Molecular and Cellular Biology Program, Institute of Food and Agricultural Sciences, University of Florida, Gainesville, FL 32611, USA

Introduction

Misfolded isoform of the prion protein, named pathogenic prion protein (PrP^{Sc}), is the infectious agent that cause transmissible spongiform encephalopathy (TSE) in human and animals [1] [In cattle, the TSE was usually called BSE (bovine spongiform encephalopathy) or mad cow disease.]. The cellular prion protein (PrP^C), a cell membrane glycoprotein, is primarily detected in neuronal tissue [2] and may be involved in signal transduction [3, 4]. The conversion from normal PrP^C to PrP^{Sc} is recognized as the key event to develop prion disease based on the "protein-only" hypothesis [5]. It has been justified that PrP^C-deficient (*PRNP*^{-/-}) mice are resistant to TSE and do not propagate infectious PrP^{Sc} without apparent developmental or behavioral defects [6–9]. Therefore, suppression of

endogenous PrP^C expression could inhibit endogenous or exogenous PrP^{Sc} formation and accumulation and thereby protect individuals from prion diseases.

Currently, cattle are recognized as potential bioreactor to produce human-use products besides milk and meat, and BSE in cattle may be a concern in the application of animal products for human use. Accordingly, it is prudent to produce human-use proteins in BSE-free cattle. During the past few years, gene targeting technology has been successfully applied to produce prion-resistant cattle [10, 11]. Within this strategy, bovine fibroblast cells were transfected with the *PRNP* gene targeting vector. After antibiotic selection, cells which undergo homologous recombination were used as donors to produce BSE-resistant cattle via nuclear transfer. However, it is technically complicating, time-consuming and costly since the inherent efficiency of the homologous recombination in somatic cells is extremely low.

RNA interference (RNAi), a conserved post-transcriptional gene silencing technology, provides a wide and powerful tool to specifically silence both endogenous protein-coding and exogenous pathogenic gene expression [12]. With RNAi, small interfering RNAs (siRNAs), which is processed from long double-stranded RNAs (dsRNAs) by the dsRNA endonuclease Dicer, can be bound to complementary mRNA and trigger specific mRNA degradation. In mammalian cells, synthetic siRNAs can be transferred into cells and induce transient gene silencing. However, the suppression effect lasts only several days because of the lack of siRNA amplification machinery in mammalian cells. Consequently, stable gene transfer and vector-based siRNA expression systems have been developed in order to resolve this problem. It has been found RNA polymerase III promoters, such as U6 or H1, could drive short hairpin RNAs (shRNAs) transcription from DNA templates, and these shRNAs subsequently are cleaved by the Dicer to produce siRNAs to introduce mRNA degradation in mammalian cells [13–16].

In the previous studies [17–20], knockdown of the prion gene by RNAi was usually carried out in transgenic mice or cell lines which transiently or stably expressed the prion protein. However, differences may exist between the transgenic *PRNP* mRNA and the wild type mRNA in terms of the length and the spatial structure so as to affect screening of the effective shRNAs. Therefore, it is necessary to perform shRNAs screen in cells which naturally express the prion gene.

Here in the present study, we detected the prion protein gene expression in bovine fibroblast cells and established a robust method to screen effective shRNAs to knockdown the prion gene expression in bovine fibroblast cells.

Materials and methods

Construction of the shRNA expression vectors

Invitrogen's RNAi Designer (<https://rnaidesigner.invitrogen.com/rnaiexpress/design.do>) was utilized to design shRNA sequences against bovine *PRNP* mRNA sequence (GenBank accession No.NM_181015) and coding domain sequence (GeneBank accession No.AY247262). One scrambled shRNA control was specifically designed. Two complementary single-stranded DNA oligonucleotides of each shRNA were chemically synthesized by Shanghai Sangon Biotechnology Co. Ltd (China) and then annealed to generate double-stranded oligonucleotides (ds oligo). Subsequently annealed ds oligo was cloned into *Bam*HI/*Hind*III linearized pGenesil-1 vector (Wuhan Genesil Biotechnology Co. Ltd., China) which contains U6 promoter to transcribe shRNA. DNA sequencing was performed to verify the sequence of the ds oligo insert.

RNA isolation and reverse transcription

Total RNA were isolated from bovine fibroblast cells with Qiagen RNeasy[®] Mini kit (Qiagen, Germany) according to the manufacturer's instructions. The integrity of isolated total RNA was analyzed by 0.7% agarose gel electrophoresis. 2–5 µg total RNA were reverse transcribed by SuperScript[™] III Reverse Transcriptase (Invitrogen, USA) with oligo(dT)₁₈ primers.

Construction of the psiCHECK[™]-2-*PRNP* vectors

The bovine *PRNP* mRNA was amplified by RT-PCR with primers listed in Table 1. One 965 bp fragment spans exon2 and exon3, and the other 767 bp fragment spans the 3' untranslated region. One microliter of undiluted cDNA from the RT reaction was employed as template for each 25 µl PCR reaction. The PCR condition was: 94°C for 5 min; 35 cycles of 94°C for 30 s, 58°C for 30 s and 72°C for 50 s; 72°C for 10 min. The PCR products were purified and digested by *Xho*I (TaKaRa, Japan) and *Not*I (TaKaRa, Japan), and finally cloned into *Xho*I/*Not*I linearized psiCHECK[™]-2 vector (Promega, USA). DNA sequencing was conducted to verify the sequence.

Cell culture and transfection

Bovine fibroblast cells and human embryonic kidney 293 cells (HEK-293) were cultured in Dulbecco's Modified Eagle Medium (DMEM; Gibco BRL, USA) supplemented with 10% fetal bovine serum (FBS; HyClone, USA) at 37.5°C under 5% CO₂. Cells were seeded in 24-well plates or 6-well plates, and cultured for one day to obtain 70–90%

Table 1 PCR primers used in the present study

Primer name	Gene	NCBI accession No.	Location	Primer sequence(5' → 3')	Length of products
psiCHECK-F1 ^a	<i>PRNP</i>	NM_181015	Exon 2	TGACTCGAGTCAACCAAGCCGAAGCATCTG	965 bp
psiCHECK-R1 ^a	<i>PRNP</i>	NM_181015	Exon 3	TATGCGGCCGCGAAATGAGACACCACCACTAC	
psiCHECK-F2 ^a	<i>PRNP</i>	NM_181015	3' UTR	TCACTCGAGCGACTGAGTGACTGAACTGAG	767 bp
psiCHECK-R2 ^a	<i>PRNP</i>	NM_181015	3' UTR	ATAGCGGCCGCTGAACCTTTTAGCCAACCCAG	
RT-F ^b	<i>PRNP</i>	NM_181015	Exon 2	AAATCCAACCTGAGCTGAATC	843 bp
RT-R ^b	<i>PRNP</i>	NM_181015	Exon 3	GGTTGCCCTATCTACTATG	
Q-83F ^{c*}	<i>PRNP</i>	NM_181015	Exon 2	GTTTCAACCAAGCCGAAGCA	134 bp
Q-195R ^{c*}	<i>PRNP</i>	NM_181015	Exon 3	CCAGGATCCAACCTGCTATGTG	
GAPDH-F ^{d*}	<i>GAPDH</i>	NM_001034034	Exon 11	CGACTTCAACAGCGACTCAC	120 bp
GAPDH-R ^{d*}	<i>GAPDH</i>	NM_001034034	Exon 12	CCCTGTTGCTGTAGCCAAATTC	

^a Primers used for cloning fragment of the *PRNP* cDNA to construct the psiCHECKTM-2-*PRNP* vectors

^b Primers used for RT-PCR and semi-quantitative RT-PCR analysis of the *PRNP* mRNA expression in bovine fibroblast cells

^c Primers used for real-time RT-PCR analysis of the *PRNP* mRNA expression in bovine fibroblast cells

^d Primers for housekeeping genes used for standardization of real-time and semi-quantitative RT-PCR

* Primers designed by Primer Express Software (Applied Biosystems)

CTCGAG, *Xho*I restriction site; GCGGCCGC, *Not*I restriction site

confluence. Then, transfection was performed using LipofectamineTM 2000 reagent (Invitrogen, USA) according to the manufacturer's instructions.

Screening of the effective shRNAs using double-luciferase detection system

HEK-293 cells plated in 24-well plates were grown to 70–90% confluence. Individual wells were transfected with 500 ng of plasmid DNA (210 ng of the psiCHECK-2TM-*PRNP* plasmid and 290 ng of the pGenesil-1 shRNA expression vector). Sixty hours post-transfection, *Renilla* and firefly luciferase activities were measured with the Dual-GloTM Luciferase Assay System (Promega, USA). To evaluate the suppression levels, the ratio of *Renilla*/Firefly in cells transfected with each test shRNA were compared to that in cells transfected with scrambled shRNA.

Semi-quantitative and real-time RT-PCR

Sixty hours after bovine fibroblast cells transfected with the pGenesil-1 shRNA expression vectors, cells were sorted by fluorescence-activated cell sorting (FACS; DakoCytomation, Inc., Ft. Collins, USA), and GFP positive (GFP⁺) cells were collected for total RNA isolation. Semi-quantitative and real-time RT-PCR were used to detect the *PRNP* mRNA expression level. The semi-quantitative RT-PCR products covered full length of the *PRNP* coding region, and the PCR condition was: 94°C for 5 min; 35 cycles of 94°C for 30 s, 56°C for 30 s and 72°C for 50 s; 72°C for 10 min. Real-time RT-PCR was performed using an ABI

Prism[®] 7900HT Sequence Detection System (Applied Biosystems, USA). A standard PCR protocol was used for all primers: 50°C for 2 min; 95°C for 10 min; 40 cycles of 95°C for 20 s, 60°C for 1 min; followed by 95°C for 15 s, 60°C for 15 s, 95°C for 15 s to draw dissociation curve. Relative expression levels of the *PRNP* gene were normalized to GAPDH expression levels. All primers were shown in Table 1.

Western blot

Sixty hours after bovine fibroblast cells transfected with the pGenesil-1 shRNA expression vectors, cells were sorted by FACS, and GFP⁺ cells were collected. These GFP⁺ cells and untransfected bovine fibroblast cells were washed twice with Dulbecco's Phosphate-Buffered Saline (DPBS; Gibco BRL, USA), and then lysed with immunoprecipitation(IP) cell lysis buffer (100 µl/10⁶ cells; Beyotime Institute of Biotechnology, China). After 30 min incubation on ice, the cell lysates were centrifuged at 4°C, 13,000×g for 5 min. The supernatants were collected for western analysis. Protein concentration of each sample was measured by BCA Protein Assay Kit (Beyotime Institute of Biotechnology, China) following the manufacturer's instructions. Protein samples were separated by 12% SDS-PAGE gel and transferred to PVDF (Polyvinylidene Fluoride) membranes (GE Healthcare, UK). For the *PRNP* gene expression detection, the membranes were incubated with rabbit anti-prion protein polyclonal antibody (Abcam Inc., USA) at room temperature for 2 h and stained by the secondary HRP-conjugated goat anti-rabbit IgG antibody

(Santa Cruz Biotechnology, Inc., USA) for 1 h. Then, the membranes were visualized using SuperSignal West Dura Extended Duration Substrate (Pierce Manufacturing, Inc., USA). β -actin was used as internal positive control in this experiment.

Statistical analysis

The real-time RT-PCR data were analyzed by the comparative C_T method. Values were shown as means \pm SEM.

Results

Detection of the prion protein gene expression in bovine fibroblast cells

RT-PCR analysis indicated the *PRNP* gene was transcriptional active in bovine fibroblast cells (Fig. 1a, b), and the 26 kDa, non-glycosylated PrP^C, could be detected in the protein lysate from bovine fibroblast cells (Fig. 1c). As shown in Fig. 1d, different amount of the protein lysate from bovine fibroblast cells was analyzed, and the prion protein could be clearly seen in 5 μ g total protein lysate.

Screening of the effective shRNAs using double-luciferase detection system

Seven shRNAs, five from the *PRNP* coding domain sequence and two from the *PRNP* mRNA 3' untranslated (3' UTR) region, were designed with Invitrogen's RNAi Designer. To facilitate screening of the effective shRNAs against the prion protein, a *PRNP* mRNA fragment was subcloned into downstream of the *Renilla* luciferase coding region within the psiCHECK-2TM vector. The psiCHECK-2-*PRNP* expression vector would produce a fusion mRNA containing the coding sequence of the *Renilla* luciferase




Fig. 1 Detection of the prion gene expression in bovine fibroblast cells. *BFC* bovine fibroblast cells, *BF* brain of bovine fetus, *BA* brain of adult cattle. **a** Analysis of the total RNA by agarose gel electrophoresis. **b** RT-PCR analysis of the *PRNP* mRNA expression in bovine fibroblast cells. *NC* negative control of reverse transcript, *G* bovine genomic DNA. The prion gene is expressed in bovine fibroblast cells. **c** Western blot analysis of the prion protein expression in bovine fibroblast cells. **d** Western blot analysis of different amount of total protein from bovine fibroblast cells. Prion protein could be detected in 5 μ g total protein lysate by western blot




Fig. 2 Screening of the effective shRNAs using double-luciferase detection system in HEK-293 cells. The psiCHECK-2-*PRNP* and shRNA expression vectors were cotransfected with HEK-293 cells. The suppression level of different shRNA targeting to *PRNP* was indicated by the *Renilla* activity normalized to firefly luciferase activity. All data are presented as the percentage of Rluc/Fluc compared with the control unrelated shRNA, and the value are an average of four independent experiments, and actual percentages and standard deviations for the shRNAs are as follows: shP 24.06 \pm 4.46%, sh1 29.05 \pm 3.55%, sh2 27.16 \pm 1.74%, sh3 27.40 \pm 3.65%, sh4 22.16 \pm 1.02%, sh5 19.10 \pm 1.11%, sh6 6.94 \pm 0.23%, sh7 8.14 \pm 0.58%, scr 100 \pm 4.53%. *shP* shRNA against *Renilla* luciferase, *sh1-7* seven shRNAs at different target sites to *PRNP* mRNA, *scr* scrambled shRNA control

followed by a non-translated *PRNP* mRNA as well as the Firefly luciferase which acts as a means of normalization. Following HEK-293 cells co-transfected with the psiCHECK-2-*PRNP* and the shRNA expression vectors, the *Renilla*/Firefly luciferase activity ratio could indicate the suppression degree of the *PRNP* mRNA expression. As shown in Fig. 2, all of the seven shRNAs could efficiently reduce *Renilla* luciferase expression. This result demonstrated that human U6 promoter could effectively drive shRNA transcription in HEK-293 cells and all of the shRNAs were effective to inhibit the *PRNP* mRNA expression.

Suppression of the prion protein gene expression in bovine fibroblast cells

Transient transfection of the bovine fibroblast cells was conducted to detect the suppression of the prion gene expression by each shRNA expression vector. As the transfection efficiency of the bovine fibroblast cells was low, around 25%, in this research, FACS was used to enrich cells which were transfected with the shRNA expression vectors, and the following detection was carried out in these cells. Out of the seven shRNA expression vectors, four resulted in obvious reductions in the *PRNP* mRNA expression level compared to the non-transfected cells (Fig. 3a). The *PRNP* mRNA expression level was reduced by 35.7, 60.2, 55.1 and 62.9%, respectively (Fig. 3b).

It was also shown that the prion protein level was reduced by the shRNA transfection when 5 μ g total protein lysate was analyzed (Fig. 3c).




Fig. 3 Suppression of the prion protein gene expression by different shRNA expression vectors in bovine fibroblast cells. *sh1–7* seven shRNAs at different target sites to the *PRNP* mRNA, *scr* scrambled shRNA control, *con* non-transfected bovine fibroblast cells, *CK* bovine genome control. **a** Semi-quantitative RT-PCR analysis of the *PRNP* mRNA expression level. Total RNA isolated from bovine fibroblast cells transfected with different shRNAs was analyzed by agarose gel electrophoresis. After reverse transcription, GAPDH was amplified as internal control. **b** Real-time RT-PCR analysis of the *PRNP* mRNA expression level in bovine fibroblast cells transfected with different shRNA expression vectors. The *PRNP* mRNA expression was normalized to GAPDH mRNA expression and denoted as a *PRNP*/GAPDH ratio. Data from three independent experiments, and the actual percentages and standard deviations for the shRNAs are as follow: sh1 81.57 ± 2.88%, sh2 100.35 ± 2.70%, sh3 64.28 ± 2.86%, sh4 82.55 ± 2.16%, sh5 39.76 ± 0.46%, sh6 44.89 ± 4.55%, sh7 37.14 ± 4.23%, scr 87.76 ± 3.20%, con 100 ± 7.67%. **c** Western blot analysis of the prion protein expression level in bovine fibroblast cells transfected with different shRNA expression vectors. Amount of total protein applied was 5 µg

Discussion

In the present study, we used DNA vector-based siRNA expression system to silence bovine *PRNP* gene expression not only in HEK-293 cells but also bovine fibroblast cells. Human U6 promoter was used to drive siRNA expression from the DNA templates and seven target sites were designed. Finally, we found four effective target sites that could down-regulate the prion gene expression in bovine fibroblast cells.

A fragment of the bovine *PRNP* mRNA sequence was inserted into the *Renilla* luciferase mRNA downstream region, thereby, a fusion mRNA containing the coding sequence of the *Renilla* luciferase followed by a non-translated *PRNP* mRNA was transcribed after the transfection of the psiCHECK-2-*PRNP* expression vector. If the siRNA transcribed from the DNA vector could bind to the

non-translated *PRNP* mRNA of the fusion mRNA and induce mRNA degradation, the coding sequence of the *Renilla* luciferase was degraded simultaneously. So the ratio of the expression level of *Renilla* luciferase, which is normalized by the firefly luciferase expression level, could indicate the silencing efficiency of individual target sites. As shown in Fig. 2, all of the seven siRNAs displayed almost the same inhibition degree compared with the siRNA against *Renilla* luciferase. This result suggested that the human U6 promoter could effectively drive siRNA transcribed from the DNA templates in HEK-293 cells.

In bovine fibroblast cells, the efficiency of cell transfection was around 25%. Therefore, after the transfection of the shRNA expression vectors, FACS was used to collect positive cells which would express siRNAs. And then semi-quantitative and real-time RT-PCR indicated four out of seven target sites had reduced 35.7–62.9% of the *PRNP* mRNA expression. This was different from the double luciferase detection analysis. In the psiCHECK-2-*PRNP* expression vector, the length of *PRNP* mRNA was no more than 1 kb, and the transcribed fusion mRNA may not form spatial structure. Transcribed siRNAs could easily bind to the complementary mRNA sequence and trigger RNAi process. In bovine fibroblast cells, the endogenous *PRNP* mRNA may have complicated spatial structure and this structure may block siRNA binding to the homology mRNA sequence which prevented RNAi process. Therefore, with the utilization of the double luciferase detection system, the effective target sites may not work well in vivo as in vitro, and further examination is needed.

In conclusion, four out of seven designed target sites had reduced the prion gene expression in bovine fibroblast cells, and two of them were at 3' UTR region of the *PRNP* mRNA. Due to lower cost, vector-based shRNA expression approaches can be broadly applied in creating donor cells to produce prion diseases-resistant large animals in the future.

Acknowledgments We thank Mr. Fangrong Ding and Song Li for help in cell culture. This research was supported by the National High-tech Research and Development Program of China (Grant No. 2007AA02Z168).

References

- Prusiner SB (1998) Prions. *Proc Natl Acad Sci USA* 95(23):13363–13383
- Tichopad A, Pfaffl MW, Didier A (2003) Tissue-specific expression pattern of bovine prion gene: quantification using real-time RT-PCR. *Mol Cell Probes* 17(1):5–10
- Martins VR, Brentani RR (2002) The biology of the cellular prion protein. *Neurochem Int* 41(5):353–355
- Ermonval M, Mouillet-Richard S, Codogno P, Kellermann O, Botti J (2003) Evolving views in prion glycosylation: functional and pathological implications. *Biochimie* 85(1–2):33–45

5. Prusiner SB (1991) Molecular biology of prion diseases. *Science* 252(5012):1515–1522
6. Bueler H, Fischer M, Lang Y, Bluethmann H, Lipp HP, De Armond SJ, Prusiner SB, Aguet M, Weissmann C (1992) Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. *Nature* 356(6370):577–582
7. Prusiner SB, Groth D, Serban A, Koehler R, Foster D, Torchia M, Burton D, Yang SL, De Armond SJ (1993) Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. *Proc Natl Acad Sci USA* 90(22):10608–10612
8. Manson JC, Clarke AR, Hooper ML, Aitchison L, McConnell I, Hope J (1994) 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. *Mol Neurobiol* 8(2–3):121–127
9. Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, Weissmann C (1993) Mice devoid of PrP are resistant to scrapie. *Cell* 73(7):1339–1347
10. Hirata RK, Xu C, Dong R, Miller DG, Ferguson S, Russell DW (2004) Efficient PRNP gene targeting in bovine fibroblasts by adeno-associated virus vectors. *Cloning Stem Cells* 6(1):31–36
11. Richt JA, Kasinathan P, Hamir AN, Castilla J, Sathiyaseelan T, Vargas F, Sathiyaseelan J, Wu H, Matsushita H, Koster J, Kato S, Ishida I, Soto C, Robl JM, Kuroiwa Y (2007) Production of cattle lacking prion protein. *Nat Biotechnol* 25(1):132–138
12. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* 411(6836):494–498
13. Sui G, Soohoo C, Affar el B, Gay F, Shi Y, Forrester WC, Shi Y (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. *Proc Natl Acad Sci USA* 99(8):5515–5520
14. Miyagishi M, Taira K (2002) U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells. *Nat Biotechnol* 20(5):497–500
15. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A, Salvaterra P, Rossi J (2002) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. *Nat Biotechnol* 20(5):500–505
16. Paul CP, Good PD, Winer I, Engelke DR (2002) Effective expression of small interfering RNA in human cells. *Nat Biotechnol* 20(5):505–508
17. Tilly G, Chapuis J, Vilette D, Laude H, Vilotte JL (2003) Efficient and specific down-regulation of prion protein expression by RNAi. *Biochem Biophys Res Commun* 305(3):548–551
18. Pfeifer A, Eigenbrod S, Al-Khadra S, Hofmann A, Mitteregger G, Moser M, Bertsch U, Kretzschmar H (2006) Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. *J Clin Invest* 116(12):3204–3210
19. Sutou S, Kunishi M, Kudo T, Wongsrikeao P, Miyagishi M, Otoi T (2007) Knockdown of the bovine prion gene PRNP by RNA interference (RNAi) technology. *BMC Biotechnol* 7:44
20. Gallozzi M, Chapuis J, Le Provost F, Le Dur A, Morgenthaler C, Peyre C, Daniel-Carlier N, Pailhoux E, Vilotte M, Passet B, Herzog L, Beringue V, Costa J, Tixador P, Tilly G, Laude H, Vilotte JL (2008) Prnp knockdown in transgenic mice using RNA interference. *Transgenic Res* 17(5):783–791